Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding events than rivaroxaban in patients with atrial fibrillation at moderate-to-high risk ...

Tom Nolan reviews this week’s research “Small individual gain, larger population gain” sounds like the theme for a preventive medicine conference. It’s actually the headline of an editorial about a ...

Milvexian is in three late-stage studies in AF, stroke, and acute coronary syndromes (ACS), while abelacimab is in the phase 3 LILAC-TIMI 76 in patients with AF deemed unsuitable for current OAC ...

Milvexian is in three late-stage studies in AF, stroke, and acute coronary syndromes (ACS) in the LIBERXIA programme, while abelacimab is in the phase 3 LILAC-TIMI 76 in patients with AF deemed ...

In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve ...

Areteia Therapeutic’s CEO, Jorge Bartolome, shared his company’s novel and first oral drug development to treat eosinophilic asthma. During the J.P. Morgan 43rd Annual Healthcare Conference in ...

Five- and 10-year survival lower for young individuals with cancer residing in redlined neighborhoods. (HealthDay News) — For young individuals with cancer, residence in redlined neighborhoods ...